Literature DB >> 24421253

Reply to Karch et al.

Hiroyu Hatano, Peter Bacchetti, Priscilla Y Hsue, Steven G Deeks.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24421253      PMCID： PMC4161999          DOI： 10.1093/infdis/jiu027

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  10 in total

1.  Power is indeed irrelevant in interpreting completed studies.

Authors:  Stephen J Senn
Journal:  BMJ       Date:  2002-11-30

2.  Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy.

Authors:  Guillaume J Besson; Deborah McMahon; Frank Maldarelli; John W Mellors
Journal:  Clin Infect Dis       Date:  2011-10-19       Impact factor: 9.079

3.  Randomized, placebo-controlled trial or post hoc subgroup analysis: the importance of standardized and comprehensive reporting.

Authors:  André Karch; Ralf Krumkamp; Benno Kreuels
Journal:  J Infect Dis       Date:  2014-01-12       Impact factor: 5.226

4.  The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results.

Authors:  S N Goodman; J A Berlin
Journal:  Ann Intern Med       Date:  1994-08-01       Impact factor: 25.391

5.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

6.  A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

Authors:  Hiroyu Hatano; Timothy L Hayes; Viktor Dahl; Elizabeth Sinclair; Tzong-Hae Lee; Rebecca Hoh; Harry Lampiris; Peter W Hunt; Sarah Palmer; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Barbara L Shacklett; Steven G Deeks
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

7.  A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.

Authors:  Hiroyu Hatano; Rebecca Scherzer; Yuaner Wu; Kara Harvill; Kristinalisa Maka; Rebecca Hoh; Elizabeth Sinclair; Sarah Palmer; Jeffrey N Martin; Michael P Busch; Steven G Deeks; Priscilla Y Hsue
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

8.  Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.

Authors:  Hiroyu Hatano; Matthew C Strain; Rebecca Scherzer; Peter Bacchetti; Deborah Wentworth; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; James D Neaton; Russell P Tracy; Priscilla Y Hsue; Douglas D Richman; Steven G Deeks
Journal:  J Infect Dis       Date:  2013-08-23       Impact factor: 5.226

9.  The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

Authors:  Rajesh T Gandhi; Lu Zheng; Ronald J Bosch; Ellen S Chan; David M Margolis; Sarah Read; Beatrice Kallungal; Sarah Palmer; Kathy Medvik; Michael M Lederman; Nadia Alatrakchi; Jeffrey M Jacobson; Ann Wiegand; Mary Kearney; John M Coffin; John W Mellors; Joseph J Eron
Journal:  PLoS Med       Date:  2010-08-10       Impact factor: 11.069

10.  Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.

Authors:  Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton
Journal:  PLoS Med       Date:  2008-10-21       Impact factor: 11.069
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.